Hydroxyzine Effects on Post-Lanosterol Biosynthesis in Smith–Lemli–Opitz Syndrome (SLOS) Models
Biomolecules · 2025
DOI: 10.3390/biom15040562 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomolecules, 2025. Verfasst von Zeljka Korade und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Biochemistry and Molecular Biology, College of Medicine, University of Nebraska Medical Center, Child Health Research Insti…. Hauptthemen laut MEDLINE: Smith-Lemli-Opitz Syndrome, Lanosterol. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 82 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NICHD NIH HHS, NIH/NICHD, National Institutes of Health.
Abstract (Originalsprache)
Smith–Lemli–Opitz syndrome (SLOS) is a developmental disability arising from bi-allelic pathogenic variants in the 7-dehydrocholestrol reductase (DHCR7) enzyme and the accumulation of 7-dehydrocholesterol (7-DHC). 7-DHC spontaneously oxidizes and gives rise to cytotoxic oxysterols. Our recent high-throughput screening on Dhcr7-deficient Neuro2a cells identified hydroxyzine (HYZ) as a medication that could counteract the high levels of 7-DHC. We assessed the effects of HYZ in Dhcr7-deficient Neuro2a cells, neuronal cultures and glial cultures from Dhcr7T93M/T93M transgenic mice, and human dermal fibroblasts from patients with SLOS. LC-MS/MS biochemical analyses revealed a strong modulatory effect of HYZ on post-lanosterol biosynthesis across all four SLOS models. However, the HYZ-induced biochemical changes were complex, dose-dependent, and variable across the four SLOS models. Dhcr7-deficient Neuro2a cells showed decreased 7-DHC, 8-dehydrocholesterol (8-DHC), and desmosterol (DES) levels (all p < 0.01), while neuronal and glial cultures from Dhcr7T93M/T93M transgenic mice reported 8 significantly altered analytes (all p < 0.001). Human dermal fibroblast from patients with SLOS reacted to HYZ exposure with significantly decreased 7-DHC, 7-dehydrodesmosterol (7-DHD), and dihydrolanosterol (DHL) levels (p < 0.001), coupled with elevation in zymosterol (ZYM), zymostenol (ZYME), and 8-DHC (p < 0.001). Further evaluations are required to determine if the potentially beneficial effects of decreased 7-DHC, 7-DHD and DHL levels in SLOS models and patient biomaterials are counteracted by the rise in other post-lanosterol intermediates.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Biochemistry and Molecular Biology, College of Medicine, University of Nebraska Medical Center, Child Health Research Institute, Omaha, NE 68198, USA.
- Munroe-Meyer Institute for Genetics and Rehabilitation, University of Nebraska Medical Center, Child Health Research Institute, Omaha, NE 68198, USA.
- Department of Medical Biology and Genetics, Faculty of Medicine, Josip Juraj Strossmayer University of Osijek, 31000 Osijek, Croatia.
- Department of Chemistry, Vanderbilt Institute of Chemical Biology and Vanderbilt Kennedy Center for Research on Human Development, Vanderbilt University, Nashville, TN 37240, USA.
ORCID-Profile: Zeljka Korade, Allison C Anderson, Marta Balog, Keri A Tallman, Karoly Mirnics
Förderung
- NICHD NIH HHS
- NIH/NICHD
- National Institutes of Health
Zitieren
APA
Korade, Z., Anderson, A. C., Balog, M., Tallman, K. A., Porter, N. A., & Mirnics, K. (2025). Hydroxyzine Effects on Post-Lanosterol Biosynthesis in Smith–Lemli–Opitz Syndrome (SLOS) Models. Biomolecules. https://doi.org/10.3390/biom15040562
Vancouver
Korade Z, Anderson AC, Balog M, Tallman KA, Porter NA, Mirnics K. Hydroxyzine Effects on Post-Lanosterol Biosynthesis in Smith–Lemli–Opitz Syndrome (SLOS) Models. Biomolecules. 2025. doi:10.3390/biom15040562
BibTeX
@article{Korade2025,
author = {Korade, Zeljka and Anderson, Allison C and Balog, Marta and Tallman, Keri A and Porter, Ned A and Mirnics, Karoly},
title = {Hydroxyzine Effects on Post-Lanosterol Biosynthesis in Smith–Lemli–Opitz Syndrome (SLOS) Models},
journal = {Biomolecules},
year = {2025},
doi = {10.3390/biom15040562}
}
EUVIMED